Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. (2022)
Attributed to:
Paediatric and adolescent infections
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(22)02078-5
PubMed Identifier: 36368336
Publication URI: http://europepmc.org/abstract/MED/36368336
Type: Journal Article/Review
Volume: 400
Parent Publication: Lancet (London, England)
Issue: 10366
ISSN: 0140-6736